The chair and vice chair of the evaluation committee have prepared Final Draft Guidance (FDG) on vutrisiran for treating hereditary transthyretin-related amyloidosis and submitted it to NICE.
The FDG has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FDG has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm, Thursday 2 February 2023.
This page was last updated: